The Philadelphia chromosome‐negative chronic myeloproliferative neoplasms (MPN) ‐ essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF) ‐ are acquired hematopoietic stem cell neoplasms characterized by virtually mutually exclusive driver mutations in Janus Kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL). Here, JAK2 is linked to acquired polycythemia vera.